I-FDA-evunyelwe i-Hepatitis C yezidakamizwa

Amachiza anike amazinga okunyanga aphezulu njengama-99 ekhulwini

Xa isalathisi Sovaldi (sofosbuvir) saqala ukuqala ngoSeptemba 2014, asizange nje imatshintshe ukuguqulwa kolwandle kwindlela ukusuleleka ngayo i- hepatitis C , yenze iilwimi zangezizukulwana zangaphambili ezingazange zisebenze. Kwiinyanga ezimbalwa zokufika kukaSovaldi, i-hepatitis C ehamba phambili njenge-Incivek (telaprevir) kunye ne-Victrelis (boceprevir) yakhawuleza yanyuka kwiimarike, ingabonakali kwakhona.

Ukulandela ngokukhawuleza kwizithende zeSovaldi kwakungeniswa kwezilwanyana ezongezelelweyo zezonyango ezithandathu ezinokukwazi ukunyanga ulwahlulo olubanzi lwe-hepatitis C. La machiza amasha awanikezeli kuphela iziphumo ezimbi, baye banciphisa ikhosi yeyeza kunyaka ezintathu.

Ngamazinga okunyanga ngoku angaphezu kweepesenti ezingama-95 kumaxesha amaninzi, umngeni onzima wendlela yokwandisa ukufikelela kubantu abayizigidi ezili-130 ukuya kwezi-150 abantu abanesifo esiphelele kwi-hepatitis C emhlabeni jikelele.

Nazi ezinye ezitsha ezisibhozo zonyango lwe-hepatitis C, oludweliswe ngumyalelo we-FDA imvume:

1 -

Epclusa

Ukuvunyelwa ngoJuni 28, 2016, i-Epclusa (i-sofosbuvir, i-velpatasvir) i-tablet inhlanganisela ezimbini kunye neyodwa inokukwazi ukuphatha zonke iinqununu ze-hepatitis C ezi-6 ezinkulu. Ingasetyenziselwa ukuphatha abantu nge-cirrhosis (kubandakanywa ne -cirrhosis ehlawulwayo ). I-Epclusa imiselwe kwimizuzu yesinye kwimizuzu yexesha elilodwa ukuya kwiiveki ezintandathu.

Kaninzi

2 -

Zepatier

Ivunyiwe ngoJanuwari 2016, i-Zepatier (elbasvir, i-grazoprevir) isilwanyana esibandakanyekayo sezonyango ezisetyenziselwa ukuphatha i-genotypes 1 ne-4 kunye okanye ngaphandle kwe-cirrhosis. I-Zepatier yonyango elilodwa lonyango elingafanele lilawulwe naliphi na isilwanyana. Kuthatyathwa kanye ngosuku kunye okanye ngaphandle kokutya kwiiveki ezi-12 ukuya kwi-16, kuxhomekeke kuhlobo lwe-genotype umntu analo kwaye nokuba umntu akaye waphathwa okokuqala ngenxa ye-hepatitis C.

Kaninzi

3 -

Daklinza

Kuyavunyelwa ngoJulayi 2015, iDadlinza (daclatasvir) isetyenziselwa unyango oluhlanganyelweyo ukuphatha unyango lwe-hepatitis C. I-Daklinza yayingumntu wokuqala osebenza ngokukhawuleza wokulwa ne-antibiotic ekwazi ukuphatha i-genotype 3 ngaphandle kokungezwa kwe- peginterferon okanye i- ribavirin . I-Daklinza ithathwa kunye noSovaldi kanye imihla ngemihla kunye okanye ngaphandle kokutya kwithuba leeveki ezili-12.

Kaninzi

4 -

Technivie

Ivunyiwe ngoJulayi 2015, i-Technivie (i-ombitasvir, i-paritaprevir / i-ritonavir) isilwanyana esisetyenziselwa unyango oluhlanganyelweyo ukuphatha abantu abane-infection ye-genotype 4. Amathente amathathu atywalayo aquka i-Technivie afakiwe kwi-pill pillow , i- Viekira Pak . Isilinganiso esinconywayo iipilisi ezimbini zithathwa kabini imihla ngemihla nge ribavirin eziliveki ezili-12.

Kaninzi

5 -

Viekira Pak

Kuvunyiwe ngoDisemba 2014, i-Viekira Pak yipropati ehlanganisiweyo yonyango esetyenziselwa ukunyanga i-hepatitis C yesifo sesifo se-1 nesifo esingena-cirrhosis. Ipakethi ifaka i-Technivie ye-drug ehlanganiswe kunye neziyobisi ezongezelelweyo ezibizwa ngokuba yi-dasabuvir. Isilinganisi esinconywayo iipilisi ezimbini zeTechnvie zithathwa rhoqo ngosuku kunye nokutya kunye ne-tablet enye yedasabuvir ithathwa kabini imihla ngemihla ngokutya. Ubude bonyango luvela kwiiveki ezi-12 ukuya kuma-24.

Kaninzi

6 -

Harvoni

Ivunyiwe ngo-Oktobha 2014, iHarvoni (ledipasvir, sofosbuvir) isisombululo esisisigxina sezonyango esisetyenziselwa ukuphatha unyango lwe-genotype 1 kunye no-4 okanye ngaphandle kwe-cirrhosis. Ingasetyenziselwa kwezinye iimeko ze-genotype 3. I-Harvoni yayingumntu wokuqala, ukuqulunqwa kweziyobisi ngokukodwa okungafuneki ukulawulwa kolawulo kunye ne-peginterferon okanye i-ribavirin. Imilinganiselo ephakanyisiweyo yipilisi enye imihla ngemihla ithathwa kunye okanye ngaphandle kokutya. Ubude bonyango luvela kwiiveki ezi-12 ukuya kuma-24.

Kaninzi

7 -

Sovaldi

Kuvunywe ngoDisemba 2013, iSovaldi (sofosbuvir) iyinveli yesikhombisi esisebenza ngokuthe ngqo kwi-anti-virus esetyenziselwa ukuphatha i-genotypes 1, 2, 3 kunye no-4. Ngokuxhomekeka kwi-genotype, i-ribavirin ingabandakanywa kunyango. Ukusuleleka kwintsholongwane ye-genotype, u-Sovaldi ubambisana kunye neDadlinza. Ubude bonyango luvela kwiiveki ezi-12 ukuya kuma-24.

Kaninzi

8 -

Olysio

Kuvunywe ngoNovemba 2013, i-Olysio (simeprevir) yipilisi ye-protease inhibitor-class used in combination treaty ukuphatha abantu abane-hepatitis C. I-Olysio isetyenziselwa ukudibanisa kunye ne-peginterferon kunye ne-ribavirin kwithuba leveki ezingama-24 ukuya kuma-36. Isilinganisi esinconywayo sisinye isibhebhe esithathwa imihla ngemihla ngokutya.

Kaninzi